Last reviewed · How we verify

NCT06032130

" Visual Characterization of Parkinson's Patients and Oculomotor or Perceptual Therapy"

Recruiting now Last updated 30 November 2023
What this trial tests

trial testing Clinical measurements in Parkinson Disease in 160 participants. Currently enrolling.

Timeline
29 September 2023
Primary endpoint
1 June 2025
1 June 2026

Quick facts

Lead sponsorUniversity of Valencia
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment160
Start date29 September 2023
Primary completion1 June 2025
Estimated completion1 June 2026
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

University of Valencia

Who can join

Adults 30 to 100, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parkinson's disease (PD) is the second most common neurodegenerative condition worldwide, characterised by motor symptoms, but with other symptoms such as visual impairment. The aim is to compare visual function between PD patients and healthy subjects in order to adequately characterise the visual capabilities of the PD population and perform oculomotor or perceptual therapy to find optometric solutions to slow down the visual impairment they suffer from or minimise their visual symptoms. In the first phase, non-invasive tests will be carried out, such as measuring visual acuity, refraction, pupil diameter in different lighting conditions, sensory dominance, contrast sensitivity, colour vision, stereopsis, reading speed, binocular vision, eye movements and influence on quality of life. In the second, visual oculomotor or perceptual exercises will be performed in a group of PD patients to assess whether there is stabilisation of impairment or improvement of these visual skills. These will be performed in a non-invasive way using simple and easy-to-use instruments or an application on an electronic device could be used. Finally, in the third phase, those visual skills that have been treated will be re-evaluated to assess possible changes, compared with a group of PD patients who have not undergone the visual exercises.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Parkinson's disease and reading performance.
    Herrero-Gracia A, Hernández-Andrés R, Merino CV, Muedra CP, et al · · 2025 · cited 1× · PMID 41128406 · DOI 10.1111/opo.70032

Verify or expand the search:

Other trials of Clinical measurements

Trials testing the same drug.

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other University of Valencia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06032130.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing